Search Results - subject_exact:"Pharmaforschung"

The long run economic effects of medical innovation and the role of opportunities

Bhalotra, Sonia; Clarke, Damian; Venkataramani, Atheendar S. - 2026

We leverage the introduction of the first antibiotic therapies in 1937 to examine the long-run effects of early childhood pneumonia on adult educational attainment, employment, income, and work-related disability. Using census data, we document large average gains on all outcomes, alongside...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015586904

Show 6 more versions 6

The long run economic effects of medical innovation and the role of opportunities

Bhalotra, Sonia; Clarke, Damian; Venkataramani, Atheendar S. - 2026

Book / Working Paper

The long run economic effects of medical innovation and the role of opportunities

Bhalotra, Sonia; Clarke, Damian; Venkataramani, Atheendar S. - 2026

Book / Working Paper

The long run economic effects of medical innovation and the role of opportunities

Bhalotra, Sonia; Clarke, Damian; Venkataramani, Atheendar S. - 2026 - Revised April 2026

Edition: Revised April 2026

Book / Working Paper

The long run economic effects of medical innovation and the role of opportunities

Bhalotra, Sonia; Clarke, Damian; Venkataramani, Atheendar S. - 2026

Book / Working Paper

The long run economic effects of medical innovation and the role of opportunities

Bhalotra, Sonia; Clarke, Damian; Venkataramani, Atheendar S. - 2025

Book / Working Paper

The Long Run Economic Effects of Medical Innovation and the Role of Opportunities

Bhalotra, Sonia; Clarke, Damian; Venkataramani, Atheendar S. - 2025

Book / Working Paper

Response adaptivity across clinical trials in portfolios of biomedical innovations

Li, Zaile; Chick, Stephen E.; Henderson, Shane G. - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015667015

Competition matters : uniform vs. indication-based pricing of pharmaceuticals

Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015675103

Show one more version 1

Competition matters : uniform vs. indication-based pricing of pharmaceuticals

Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune - 2025

Book / Working Paper

The impact of biomedical innovation on US mortality, 1999-2019 : evidence partly based on 286 million descriptors of 27 million PubMed articles

Lichtenberg, Frank R.; Krstovski, Kriste - 2026

We investigate whether the diseases for which there was more biomedical innovation had larger 1999-2019 reductions in premature mortality. Biomedical innovation related to a disease is measured by the change in the mean vintage of descriptors of PubMed articles about the disease. We analyze data...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015677355

Pharmaceuticals and digital health : evidence from data-driven insights on the insulin market

Bignon, Léa - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10016060618

Legalization and innovation in the cannabis market

Wang, Lucy Xiaolu; Chan, Nathan W. - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10016083374

Can the size and duration of clinical trials in new drug applications predict post-approval safety warnings?

Clark, Jeremy; Menclova, Andrea Kutinova - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015394355

A review of the literature on the new European Medical Device Regulations requirements for increased clinical evaluation

McDermott, Olivia; Kearney, Breda - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015419422

Pharmaceutical regulation and incentives for innovation in an international perspective

Dubois, Pierre - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015466930

Show one more version 1

Pharmaceutical regulation and incentives for innovation in an international perspective

Dubois, Pierre - 2025

Book / Working Paper

Disclosure and the pace of drug development

Cunnningham, Colleen; Ederer, Florian; Hodgson, Charles; … - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015467032

Modelling the global economic impact of antimicrobial resistance in humans

Countryman, Amanda M.; McDonnell, Anthony - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015405411

Firm-level innovation and the role of political capabilities : evidence for the pharmaceuticals industry

Saha, Amrita; Pozo Segura, Juan Manuel del; Palazzo, Gabriel - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015405762

Are M&As spurring or stifling innovation? : evidence from antidiabetic drug development

Malek, Jan; Seldeslachts, Jo; Veugelers, Reinhilde - 2025

This paper provides empirical evidence on which M&A deals spur innovation, and which stifle it. To do so, we consider not only the product market position of the acquiring firm, but also the position of both target and acquirer in the technology space. Focusing on the antidiabetic drugs market,...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015434666

Show 2 more versions 2

Are M&As spurring or stifling innovation? : evidence from antidiabetic drug development

Malek, Jan; Seldeslachts, Jo; Veugelers, Reinhilde - 2025

Book / Working Paper

Are M&AS spurring or stifling innovation? : evidence from antidiabetic drug development

Malek, Jan; Seldeslachts, Jo; Veugelers, Reinhilde - 2025

Book / Working Paper

Marketing authorization and strategic patenting : evidence from pharmaceuticals

Byrski, Dennis; Wang, Lucy Xiaolu - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015562837

Medical research and health care finance : evidence from Academic Medical Centers

Azoulay, Pierre; Heggeness, Misty; Kao, Jennifer L. - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015564644

When the drugs (don't) work : the role of science in product commercialization

Anckaert, Paul-Emmanuel - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015567698

Information disclosure and peer innovation : evidence from mandatory reporting of clinical trials

Hsu, Po-Hsuan; Lee, Kyungran; Moon, S. Katie; Oh, Seungjoon - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015550407

Bedside manner or technical quality? : building advocacy for clinical trial participation via rapport

Mulcahy, Rory; Piplica, Sarah; Fleischman, David - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015519581

Barracudas, Piranhas and crowds : making ideas valuable in pharmaceutical innovation through opening and closing practices of valuation

Zangerle, Katharina; Dobusch, Leonhard; Weiskopf, Richard - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015590033

Investigator racial diversity and clinical trial participation

Alsan, Marcella; Campbell, Romaine A.; Leister, Lukas; … - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015672443

Show 2 more versions 2

Investigator racial diversity and clinical trial participation

Alsan, Marcella; Campbell, Romaine A.; Leister, Lukas; … - 2023

Book / Working Paper

Investigator Racial Diversity and Clinical Trial Participation

Alsan, Marcella; Campbell, Romaine A.; Leister, Lukas; … - 2023

Book / Working Paper

Horizon scanning and drug expenditure for rare diseases : three-year predictive model in Italy 2025-2027

Marcellusi, Andrea; Cazzato, Daniela; Guarnotta, Giulio; … - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10016070655

Role of global public sector research in discovering new drugs and vaccines

Stevens, Ashley J.; Benson, David E.; Dodson, Sara E.; … - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015056452

The vaccine industry after the COVID-19 pandemic : an international perspective

Lobo, Félix - 2024

The purpose of this report is to analyze the impact that the COVID-19 pandemic has had on the vaccine industry from an international perspective. The objective is to learn from the experience and contribute to the design of better tools for future vaccine development and manufacturing, as we...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014637110

Setting pharmaceutical drug prices : what the medicare negotiators need to know about innovation and financialization

Tulum, Öner; Lazonick, William - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015099143

Did the COVID-19 pandemic propel usage of AI in pharmaceutical innovation? : new evidence from patenting data

Rathi, Sawan; Majumdar, Adrija; Chatterjee, Chirantan - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015075658

Representation and extrapolation : evidence from clinical trials

Alsan, Marcella; Durvasula, Maya; Gupta, Harsh; … - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014528129

Show one more version 1

Representation and Extrapolation : Evidence from Clinical Trials

Alsan, Marcella; Durvasula, Maya; Gupta, Harsh; … - 2022

Book / Working Paper

Acquiring R&D projects: who, when, and what? : evidence from antidiabetic drug development

Malek, Jan; Newham, Melissa; Seldeslachts, Jo; … - 2024

This paper analyzes M&A patterns of R&D projects in the antidiabetics industry. For this purpose, we construct a database with all corporate individual antidiabetics R&D projects over the period 1997 - 2017, and add detailed information on firms' technology dimension using patent information,...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014468769

Show 2 more versions 2

Acquiring R&D projects: who, when, and what? : evidence from antidiabetic drug development

Malek, Jan; Newham, Melissa; Seldeslachts, Jo; … - 2024

Book / Working Paper

Acquiring R&D projects : who, when, and what? : evidence from antidiabetic drug development

Malek, Jan; Newham, Melissa; Seldeslachts, Jo; … - 2024

Book / Working Paper

The rise of spin-offs : fueling pharmaceutical innovation through collaboration

Yashiro, Kentaro; Lim, Yeongjoo; Sengoku, Shintaro; … - 2024

Collaboration among various organizations is important for the sustainable creation of new innovative drugs. Previously, drug discovery was dominated by large pharmaceutical companies; however, various new players are now actively involved in this endeavor. Nevertheless, the factors affecting...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014518795

Funding of clinical trials and reported drug efficacy

Oostrom, Tamar - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015144357

Using artificial intelligence to advance the research and development of orphan drugs

Irissarry, Carla; Burger-Helmchen, Thierry - 2024

While artificial intelligence has successful and innovative applications in common medicine, could its application facilitate research on rare diseases? This study explores the application of artificial intelligence (AI) in orphan drug research, focusing on how AI can address three major...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015098443

The role of Information Technology and employee engagement in enhancing Knowledge Management in the pharmaceutical Research and Development process : insights from dynamic capabilities theory

Chatzifoti, Natalia; Didaskalou, Eleni A.; Chountalas, … - 2024

This study investigates the impact of Information Technology and employee engagement on the implementation of Knowledge Management within the Research and Development processes of pharmaceutical companies. Based on Dynamic Capabilities Theory, this research examines the interaction between these...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015098513

Impact of hospital decision-making on drug markets : the case of biosimilars

Kanazawa, Kyogo - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015051304

Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Michaeli, Daniel; Michaeli, Christoph T.; Albers, Sebastian - 2024

Over the past decades, US Congress enabled the US Food and Drug Administration (FDA) to facilitate and expedite drug development for serious conditions filling unmet medical needs with five special designations and review pathways: orphan, fast track, accelerated approval, priority review, and...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015131485

Health ecosystem : active pharmaceutical ingredients

2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015275965

Pharmaceutical innovation collaboration, evaluation, and matching

Liu, Qianshuo - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015182090

Competition and pharmaceutical innovation : the moderating role of size and age of leading companies in the market

Jung, Ye Lim; Yoo, Hyoung Sun - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015405937

COVID-19 biopharmaceutical innovation and industry appropriation

Philipson, Tomas J.; Fendrick, A. Mark; Kataria, Aarushi; … - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015436899

Negotiating health and autonomy : data exclusivity, healthcare policies and access to pharmaceutical innovations

Menezes, Henrique Zeferino de; Paranhos, Julia; Torres, … - 2024

This paper analyzes the debate over the international dissemination of data exclusivity as a form of protection for clinical trial data. This is a critical demand for pharmaceutical companies seeking larger market shares and longer periods of monopoly in order to recover investments in research...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014637112

Compulsory licensing as a remedy against excessive pricing of life-saving medicines

Kianzad, Behrang - 2024

The COVID-19 crisis intensified decade-long debates on the interaction between intellectual property rights (IPRs), competition law and access to affordable life-saving treatments and vaccines. Compulsory licensing of patented medicines is a tried-and-tested method to expand access, particularly...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014541546

Sustaining the integration of social objectives over time : a case-based analysis of access to medicine in the pharmaceutical industry

Bünder, Tobias; Rathert, Nikolas; Mair, Johanna - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014577841

Scientific evidence production and specialty drug diffusion

Vakratsas, Demetrios; Wang, Wei-Lin - 2024

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014582836

Valuation of Regulatory Risk on Pharmaceutical R&D

Corzo Santamaría, Teresa; Portela, José; Schwartz, … - 2026

Geopolitical tensions, supply-chain concerns and policy risk have moved to the forefront of the pharmaceutical industry. This paper develops a real options valuation model of drug R&D that captures sequential clinical investment with technical failure, stochastic costs, uncertain cash flows, and...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015611167

Weighing the Impacts of GLP-1s : Quasi-Experimental Evidence From Provider Adoption

Bock, Sam; Moshfegh, Jasmin; Zhang, Jonathan - 2026

The arrival of GLP-1 medications has been described as one of the most important health care innovations in recent years. We provide large-scale quasi-experimental evidence on their real-world impacts by exploiting variation in the eventual prescribing propensities of patients' pre-existing...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015593741

From free rider to innovator : the rise of China's drug development

Barwick, Panle Jia; Xia, Hongyuan; Xia, Tianli - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015615578

Regulatory incentives for innovation : the FDA's breakthrough therapy designation

Chandra, Amitabh; Kao, Jennifer L.; Miller, Kathleen L.; … - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10016092660

Show one more version 1

Regulatory Incentives for Innovation : The FDA's Breakthrough Therapy Designation

Chandra, Amitabh; Kao, Jennifer L.; Miller, Kathleen L.; … - 2022

Book / Working Paper

Handbook of pharmaceutical science and technology studies

2026

"This comprehensive Handbook examines innovation in the pharmaceutical sector using ideas drawn from the interdisciplinary field of science and technology studies (STS). Leading experts present diverse social science approaches to pharmaceuticals, consolidating existing research and providing an...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10016094217

The EU's open strategic autonomy in the field of pharmaceuticals : overcoming import dependencies for antibiotics through the EU authority HERA

Bayerlein, Michael - 2023

The COVID-19 pandemic and war in Ukraine have highlighted the dependence of the European Union (EU) on individual trading partners. One of the tasks of the European Commission’s new Directorate-General, the Health Emergency Preparedness and Response Authority (HERA), established in 2021, will...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10013540432

Decision criteria for partial nationalization of pharmaceutical supply chain : a scoping review

Marrone, Patrícia Véras; Mathias, Fabio Rampazzo; … - 2023

(1) Background: Any disturbance in the pharmaceutical supply chain (PSC) can disrupt the supply of medicines and affect the efficiency of health systems. Due to shortages in the global pharma supply chain over the past few years and the complex nature of free trade and its limitations when...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10013500649

Pharma Scientists Reflection on R&D in Nepalese Pharmaceuticals : A Qualitative Study

Pokharel, Post Raj - 2023

Pharmaceutical companies are greatly regulated and monitored by both the government and the public. R&D is mandatory, core, and plays a significant role in the pharmaceutical industry. Considering this aspect, a qualitative study is done taking information from eleven key pharma scientists from...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014263138

Effects of Trips Agreement on Indian Pharmaceutical Patenting

Pai, Rimpa - 2023

The TRIPS Agreement obligated India to amend its patent laws to meet the minimum standard of patent protection and patentability. In 2005, India amended its Patent Act to comply with TRIPS, which resulted in the removal of several provisions that facilitated the production and importation of...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10014347932